Research Progress on Alzheimer's Disease and Resveratrol

Yan, Yan; Yang, Huihuang; Xie, Yuxun; Ding, Yuanlin; Kong, Danli; Yu, Haibing

doi:10.1007/s11064-020-03007-0

Cited by 64 publications

(38 citation statements)

References 194 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This activation of RSV/AMPK-driven autophagy was also confirmed by our lab in a high-fat diet induced mouse model (100 mg/kg RSV, 60% kcal from fat) [ 107 ] as well as in an ischemic mouse model, where RSV (1.8 mg/kg) was delivered via intravenous tail injection [ 94 ]. Results from all these studies confirm that not only is RSV capable of entering the brain but also that activation of AMPK with RSV has the potential to improve overall AD pathology, likely through improved ROS management, reduced mitochondrial dysfunction, reduced inflammation, and increased autophagic clearance of A

peptides [ 103 , 110 , 118 , 119 ].…”

Section: Alzheimer’s Diseasementioning

confidence: 92%

Resveratrol, Metabolic Dysregulation, and Alzheimer’s Disease: Considerations for Neurogenerative Disease

Yang

Bagit

MacPherson

2021

IJMS

View full text Add to dashboard Cite

Alzheimer’s disease (AD) has traditionally been discussed as a disease where serious cognitive decline is a result of Aβ-plaque accumulation, tau tangle formation, and neurodegeneration. Recently, it has been shown that metabolic dysregulation observed with insulin resistance and type-2 diabetes actively contributes to the progression of AD. One of the pathologies linking metabolic disease to AD is the release of inflammatory cytokines that contribute to the development of brain neuroinflammation and mitochondrial dysfunction, ultimately resulting in amyloid-beta peptide production and accumulation. Improving these metabolic impairments has been shown to be effective at reducing AD progression and improving cognitive function. The polyphenol resveratrol (RSV) improves peripheral metabolic disorders and may provide similar benefits centrally in the brain. RSV reduces inflammatory cytokine release, improves mitochondrial energetic function, and improves Aβ-peptide clearance by activating SIRT1 and AMPK. RSV has also been linked to improved cognitive function; however, the mechanisms of action are less defined. However, there is evidence to suggest that chronic RSV-driven AMPK activation may be detrimental to synaptic function and growth, which would directly impact cognition. This review will discuss the benefits and adverse effects of RSV on the brain, highlighting the major signaling pathways and some of the gaps surrounding the use of RSV as a treatment for AD.

show abstract

peptides [ 103 , 110 , 118 , 119 ].…”

Section: Alzheimer’s Diseasementioning

confidence: 92%

Resveratrol, Metabolic Dysregulation, and Alzheimer’s Disease: Considerations for Neurogenerative Disease

Yang

Bagit

MacPherson

2021

IJMS

View full text Add to dashboard Cite

show abstract

“…Alzheimer's disease (AD) is the most common neurodegenerative disease that leads to the decline of cognitive function and memory. AD is characterized by the pathological accumulation of amyloid- β (A β ), neurofibrillary tangles (NFTs), and phosphorylated tau protein [ 155 ]. In addition, inflammation is thought to exacerbate the pathology of AD [ 156 ].…”

Section: Sirt1 and Cns Diseasesmentioning

confidence: 99%

The Beneficial Roles of SIRT1 in Neuroinflammation-Related Diseases

Jiao

Gong

2020

Oxidative Medicine and Cellular Longevity

197

106

View full text Add to dashboard Cite

Sirtuins are the class III of histone deacetylases whose deacetylate of histones is dependent on nicotinamide adenine dinucleotide (NAD+). Among seven sirtuins, SIRT1 plays a critical role in modulating a wide range of physiological processes, including apoptosis, DNA repair, inflammatory response, metabolism, cancer, and stress. Neuroinflammation is associated with many neurological diseases, including ischemic stroke, bacterial infections, traumatic brain injury, Alzheimer’s disease (AD), and Parkinson’s disease (PD). Recently, numerous studies indicate the protective effects of SIRT1 in neuroinflammation-related diseases. Here, we review the latest progress regarding the anti-inflammatory and neuroprotective effects of SIRT1. First, we introduce the structure, catalytic mechanism, and functions of SIRT1. Next, we discuss the molecular mechanisms of SIRT1 in the regulation of neuroinflammation. Finally, we analyze the mechanisms and effects of SIRT1 in several common neuroinflammation-associated diseases, such as cerebral ischemia, traumatic brain injury, spinal cord injury, AD, and PD. Taken together, this information implies that SIRT1 may serve as a promising therapeutic target for the treatment of neuroinflammation-associated disorders.

show abstract

“…Resveratrol inhibits c-secretase activity through the regulation of general control nonderepressible 2 (GCN2) by the autophagolysosome system, thereby effectively inhibiting the formation of Ab. In addition, as a natural activator of sirtuin 1 (Sirt1), resveratrol activates the transcriptional expression of Sirt1dependent ADAM10 (a disintegrin and metalloproteinase domain-containing protein 10), increases the production and activity of a-secretase, and reduces the production of Ab [9,20,33]. Studies have found that resveratrol can effectively prevent Ab aggregation and deposition and that the aggregation of Ab25-35 is inhibited by resveratrol in a dose-dependent manner [9,20,33].…”

Section: Discussionmentioning

confidence: 99%

Neuroprotective Effect of Trans-Resveratrol in Mild to Moderate Alzheimer Disease: A Randomized, Double-Blind Trial

Chen

et al. 2021

Neurol Ther

View full text Add to dashboard Cite

Introduction: Amyloid-beta (Ab) protein is a major component of the extracellular plaque found in the brains of individuals with Alzheimer's disease (AD). In this study, we investigated the effect of trans-resveratrol as an antagonist treatment for moderate to mild AD, as well as its safety and tolerability. Methods: This was a case-control study that enrolled 30 selected patients who had been clinically diagnosed with moderate to mild AD. These patients were randomly divided into two groups, namely, a placebo group (n = 15) and a trans-resveratrol group (n = 15) who received 500 mg trans-resveratrol orally once daily for 52 weeks. Brain magnetic resonance imaging

show abstract

Research Progress on Alzheimer's Disease and Resveratrol

Cited by 64 publications

References 194 publications

Resveratrol, Metabolic Dysregulation, and Alzheimer’s Disease: Considerations for Neurogenerative Disease

Resveratrol, Metabolic Dysregulation, and Alzheimer’s Disease: Considerations for Neurogenerative Disease

The Beneficial Roles of SIRT1 in Neuroinflammation-Related Diseases

Neuroprotective Effect of Trans-Resveratrol in Mild to Moderate Alzheimer Disease: A Randomized, Double-Blind Trial

Contact Info

Product

Resources

About